233 related articles for article (PubMed ID: 33688789)
1. Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma.
Lau DK; Athauda A; Chau I
Expert Opin Pharmacother; 2021 Aug; 22(11):1429-1441. PubMed ID: 33688789
[No Abstract] [Full Text] [Related]
2. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
[TBL] [Abstract][Full Text] [Related]
3. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
4. [Perioperative treatment for resectable esogastric adenocarcinoma].
Dabout V; de la Fouchardière C; Voron T; André T; Huguet F; Cohen R
Bull Cancer; 2023 May; 110(5):521-532. PubMed ID: 35965103
[TBL] [Abstract][Full Text] [Related]
5. Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?
Cartwright E; Keane FK; Enzinger PC; Hong T; Chau I
Am Soc Clin Oncol Educ Book; 2018 May; 38():280-291. PubMed ID: 30231360
[TBL] [Abstract][Full Text] [Related]
6. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
[TBL] [Abstract][Full Text] [Related]
7. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Chua YJ; Cunningham D
Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804
[No Abstract] [Full Text] [Related]
8. Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.
Ku GY; Ilson DH
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1953-64. PubMed ID: 19046115
[TBL] [Abstract][Full Text] [Related]
9. [Exploration and thoughts on perioperative treatment of advanced gastric cancer].
Li YF; Zhou ZW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):112-117. PubMed ID: 33508915
[TBL] [Abstract][Full Text] [Related]
10. Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia.
Sasako M
Expert Rev Anticancer Ther; 2019 Nov; 19(11):939-945. PubMed ID: 31661989
[No Abstract] [Full Text] [Related]
11. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
Sandler S
Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
[TBL] [Abstract][Full Text] [Related]
12. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches.
Davidson M; Chau I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):327-338. PubMed ID: 29431018
[TBL] [Abstract][Full Text] [Related]
13. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
14. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
15. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
16. Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects.
Merrett ND
World J Gastroenterol; 2014 Sep; 20(36):12892-9. PubMed ID: 25278686
[TBL] [Abstract][Full Text] [Related]
17. Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.
Piro G; Carbone C; Santoro R; Tortora G; Melisi D
Expert Rev Mol Diagn; 2018 Apr; 18(4):357-370. PubMed ID: 29544370
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
[TBL] [Abstract][Full Text] [Related]
20. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond.
Choi AH; Kim J; Chao J
World J Gastroenterol; 2015 Jun; 21(24):7343-8. PubMed ID: 26139980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
